|New Threads Only:|
|New Threads & Replies:|
Forum List » Guru News and Commentaries|
Guru News, Stock picks and commentaries
David Einhorn Increases Position in CareFusion Corp. by 33%
Posted by: hyperman299 (IP Logged)
Date: August 16, 2011 04:21PM
David Einhorn increased his position in CareFusion Corp. (CFN) by 33% at the average price of $24.76 on 08/15/2011, as reported in the latest 13G filings by David Einhorn. He owns 12,668,724 shares. CareFusion is a global corporation serving the health care industry with products and services that help hospitals measurably improve the safety and quality of care. CareFusion Corp. has a market cap of $5.72 billion; its shares were traded at around $24.76 with a P/E ratio of 15.23 and P/S ratio of 1.62.
Andreas Halvorsen bought 1,934,612 shares in the quarter that ended on 03/31/2011, which is 0.47% of the $11.95 billion portfolio of Viking Global Investors LP. John Keeley owns 188,290 shares as of 06/30/2011, an increase of 23.69% from the previous quarter. This position accounts for 0.0835% of the $6.13 billion portfolio of Keeley Fund Management. Edward Owens owns 4,284,654 shares as of 06/30/2011, an increase of 20.07% from the previous quarter. This position accounts for 0.5852% of the $19.89 billion portfolio of Vanguard Health Care Fund. George Soros owns 9,200 shares as of 06/30/2011, a decrease of 67.03% of from the previous quarter. This position accounts for 0.0035% of the $7.11 billion portfolio of Soros Fund Management LLC.
CareFusion recently reported its fourth quarter and fiscal 2011 results. Revenue for the fourth quarter of fiscal 2011 increased 4% to $964 million on a reported basis and 2% on a constant currency basis, driven primarily by increased sales in the Infusion, Dispensing and Infection Prevention businesses. Operating income was $149 million and income from continuing operations was $96 million, or $0.42 per diluted share.
"Growth in our Infusion, Dispensing and Infection Prevention businesses, gross margin expansion and the benefit of strong spending controls drove double digit improvements in our adjusted operating earnings for the quarter and for the year," said Kieran Gallahue, chairman and CEO. "We continue to make progress in optimizing our product portfolio and expanding our geographical footprint. We recently acquired pharmacy automation innovator Rowa, enabling us to expand our Pyxis platform outside the U.S."
Guru Discussed: David Einhorn: Current Portfolio, Stock Picks
Stocks Discussed: CFN,
Disclaimers: GuruFocus.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The gurus may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.